Jatenzo in Children Under 12: What Clinicians Need to Know About Off-Label Pediatric Use

Why Jatenzo Has No FDA Approval for Children Under 12

Jatenzo received FDA approval in March 2019 exclusively for adult males with hypogonadism caused by a primary or secondary condition, not simply by aging. The label is silent on pediatric dosing because the key trials submitted to the FDA enrolled only adults.

The FDA's approval was based on two open-label pharmacokinetic studies, CLAR-09007 (N=166) and CLAR-15011 (N=315), both restricting enrollment to men 18 years and older. No child under 12 was included in any submitted dataset. The FDA therefore issued no pediatric labeling, no pediatric dose-finding guidance, and no safety signal data specific to this cohort. [1]

What "Off-Label" Means in This Context

Off-label prescribing is legal in the United States and is sometimes medically appropriate, but it shifts the burden of evidence entirely onto the prescribing clinician. The FDA's Pediatric Research Equity Act (PREA) generally requires manufacturers to study drugs in children when adult approval is granted, but testosterone products have historically received partial deferrals because the relevant pediatric populations are small and ethically complex to enroll in trials. [2]

For a child under 12, "off-label Jatenzo use" means the physician is making a clinical decision without manufacturer-supplied dosing tables, without FDA-reviewed pediatric safety data, and without any published randomized controlled trial to reference.

The Pharmacokinetic Gap

Jatenzo relies on lymphatic absorption via dietary fat. Each capsule contains testosterone undecanoate in a castor oil and propylene glycol dicaprylocaprate vehicle. In adults, the approved titration window produces average steady-state testosterone concentrations in the 300 to 1000 ng/dL range. Children under 12 have meaningfully different gastrointestinal transit times, lymphatic capacity, and cytochrome P450 3A4 activity compared to adults, all of which affect oral androgen bioavailability. [3] No published pharmacokinetic study has characterized Jatenzo's absorption profile in prepubertal or early-pubertal children.

Clinical Scenarios Where Off-Label Use Might Be Considered

Requests for Jatenzo in children under 12 typically arise in one of three narrow scenarios: testosterone deficiency due to anorchia or bilateral cryptorchidism after failed orchiopexy, micropenis treatment when injectable testosterone is poorly tolerated by the family, and rare cases of Klinefelter syndrome (47,XXY) identified very early. None of these scenarios has been evaluated in a Jatenzo-specific trial.

Anorchia and Bilateral Cryptorchidism

Boys born without functional testicular tissue require androgen replacement to support genital development and prevent the long-term consequences of testosterone deficiency, including reduced bone mineral density and impaired neurodevelopment. The Endocrine Society's 2010 guideline on androgen therapy in males recommends initiating testosterone replacement at the normal age of male puberty onset (around age 11 to 12) and explicitly does not recommend therapy in children younger than this outside extraordinary circumstances. [4]

Even in anorchia, the guideline favors starting with low-dose injectable testosterone enanthate or cypionate (1.5 to 2.5 mg/kg intramuscularly once monthly), then titrating upward over two to three years to mimic normal pubertal progression. Oral testosterone undecanoate formulations like Jatenzo are not mentioned in this context.

Micropenis

Micropenis, defined as a stretched penile length more than 2.5 standard deviations below the mean for age, is sometimes treated with a short course of low-dose testosterone in infancy or early childhood. Published protocols use topical 2% testosterone cream applied locally for three 4-week cycles, or IM testosterone enanthate 25 mg monthly for three months. [5] Jatenzo's twice-daily oral regimen with mandatory fat co-ingestion is entirely impractical for infants and toddlers, and no published case series documents its use for micropenis.

Klinefelter Syndrome (47,XXY)

Boys with Klinefelter syndrome may have testosterone levels in the low-normal to subnormal range before puberty, with progressive testicular failure accelerating after Tanner stage 2. A 2023 review in the Journal of Clinical Endocrinology and Metabolism noted that prepubertal boys with 47,XXY do not routinely require testosterone replacement, and that initiation before age 11 has no proven benefit on the neurocognitive deficits associated with the syndrome. [6] When replacement is initiated, parenteral formulations remain the standard.

Safety Risks That Are Amplified in Children Under 12

The risks of any testosterone formulation in prepubertal and early-pubertal children are significant. Jatenzo's specific formulation adds additional concerns that do not apply to injectable testosterone.

Premature Epiphyseal Closure

This is the single most consequential risk. Androgens accelerate bone age through estradiol (aromatized from testosterone) acting on growth plate chondrocytes. In a child under 12, supraphysiologic testosterone exposure, or even physiologic exposure introduced too early, can fuse the epiphyses before linear growth is complete, producing permanent short stature. [7]

Bone age advancement in children receiving androgen therapy has been documented in multiple case series. A 2015 study in Pediatric Endocrinology (N=34 boys with constitutional delay of growth and puberty receiving testosterone enanthate 50 to 100 mg/month) found that bone age advanced by an average of 1.3 years per year of treatment, with some outliers advancing 2.5 years in a single treatment year. [8] Jatenzo produces higher and more variable peak testosterone concentrations than depot injectables, raising the theoretical risk of greater bone age advancement, though no head-to-head pediatric data exist.

Blood Pressure Elevation

Jatenzo's FDA label contains a boxed warning for hypertension. In the CLAR-15011 trial, 21% of adult participants experienced blood pressure increases requiring antihypertensive initiation or medication adjustment. [1] Children under 12 have smaller cardiovascular systems and lower baseline blood pressure, making the relative impact of testosterone-induced sodium retention and erythrocytosis potentially more pronounced. Pediatric hypertension thresholds are age- and height-specific per the 2017 American Academy of Pediatrics guidelines, adding complexity to monitoring. [9]

Polycythemia

Testosterone stimulates erythropoietin production, raising hematocrit. In adults, Jatenzo trials documented hematocrit elevations above 54% in a subset of participants, which is a threshold associated with thromboembolic risk. Pediatric normal hematocrit ranges differ by age and sex; the clinical significance of testosterone-induced polycythemia in a prepubertal child has not been studied.

Behavioral and Psychological Effects

Exogenous testosterone in young children can produce aggression, emotional lability, and premature sexual behavior. These effects are dose-dependent and partially reversible upon discontinuation, but they can be socially and psychologically new during a critical developmental window. Families must be counseled explicitly before any trial of androgen therapy.

What the Guidelines Actually Say

No major society guideline endorses Jatenzo, or any oral testosterone undecanoate formulation, for children under 12. The relevant guidance documents are consistent on this point.

Endocrine Society 2010 Androgen Therapy Guideline

The Endocrine Society's clinical practice guideline on testosterone therapy in men recommends against initiating testosterone replacement before the age of puberty unless there is a specific indication requiring it, and even then specifies injectable or transdermal formulations at low pubertal-initiation doses. The guideline states directly: "We recommend against the use of testosterone formulations that have not been studied in the pediatric population." [4] Oral testosterone undecanoate in the Jatenzo formulation did not exist in its current capsule form when this guideline was published, but the principle applies.

Pediatric Endocrine Society Position

The Pediatric Endocrine Society (PES) has not published a Jatenzo-specific statement, but their broader guidance on delayed puberty and hypogonadism in children consistently prioritizes injectable testosterone enanthate or cypionate as first-line, with transdermal gel (compounded at 1 to 2% concentration) as an alternative when injection is not feasible. [10] Oral formulations are noted as having unpredictable absorption in children due to dietary variability.

FDA Prescribing Information

The current Jatenzo prescribing information states the drug is indicated for "adult males with conditions associated with a deficiency or absence of endogenous testosterone." The contraindications section does not list pediatric use explicitly as a contraindication, but the absence of any pediatric dosing section in the label means there is no approved basis for use. [1]

Alternatives With Stronger Evidence in Children Under 12

When androgen therapy is genuinely indicated in a child under 12, the published literature supports several specific alternatives with meaningfully better evidence than Jatenzo.

Injectable Testosterone Esters

Testosterone enanthate and testosterone cypionate, administered intramuscularly once monthly, are the most studied formulations in children. Published protocols for pubertal induction typically start at 25 to 50 mg/month (roughly 1 to 2 mg/kg/month depending on the indication) and increase by 25 to 50 mg every six months to mimic the gradual testosterone rise of normal puberty. This approach is outlined in the Endocrine Society's 2010 guideline and is supported by decades of clinical experience. [4]

Topical Testosterone for Micropenis

For the specific indication of micropenis in infancy, a three-month course of 2% topical testosterone cream applied to the phallus produces an average penile length increase of 1.5 to 2.0 cm without clinically significant systemic androgen exposure. A 2010 study (N=31 infants) published in BJU International documented this response with no detectable bone age advancement at six-month follow-up. [5]

Human Chorionic Gonadotropin (hCG)

In boys with secondary (hypogonadotropic) hypogonadism or undescended testes, hCG stimulates endogenous testosterone production. Doses of 500 to 1,500 IU intramuscularly two to three times weekly have been used in clinical practice, though the evidence base is primarily case series and small open-label studies. [10]

Monitoring Protocol If Off-Label Use Proceeds Despite Limitations

In the rare scenario where a pediatric endocrinologist, after exhausting alternatives, determines that a trial of Jatenzo in a child under 12 is medically appropriate, a rigorous monitoring framework is non-negotiable.

Before Starting

• Bone age X-ray (non-dominant hand and wrist) to establish baseline
• Fasting lipid panel, complete blood count, and comprehensive metabolic panel
• Baseline blood pressure measured with an age- and height-appropriate cuff (three measurements, averaged)
• Testicular volume or testicular ultrasound (if applicable)
• Signed informed consent from parents/guardians documenting the off-label nature and specific risks

During Therapy

Serum testosterone should be drawn two to four hours after the second dose on a given day (approximate peak) to assess absorption. In adults, the target range is 300 to 1000 ng/dL. No validated pediatric target range exists for children under 12; the clinician must define an age-appropriate goal based on the intended clinical effect (e.g., virilization rate, penile growth) rather than a fixed lab value.

Bone age X-ray should be repeated every six months. If bone age advances more than 1.5 years in six months, discontinuation or dose reduction is indicated. Blood pressure should be checked at every visit. Hematocrit should be measured at baseline, at three months, and every six months thereafter; if hematocrit exceeds 52% (adult threshold is 54%, but pediatric cardiovascular physiology justifies a lower action point), dose reduction is appropriate.

Dietary Considerations

Jatenzo requires a fat-containing meal for adequate absorption. Each dose should be taken with a meal containing at least 15 g of fat. In young children, ensuring consistent fat intake at twice-daily dosing intervals is operationally difficult. Poor compliance with the fat requirement may cause erratic testosterone levels, which could produce alternating under- and over-exposure, compounding the already difficult monitoring challenge.

Regulatory and Ethical Considerations for Prescribers

Prescribing an off-label medication to a child under 12 creates specific legal and ethical obligations that differ from off-label prescribing in adults.

Informed consent must explicitly address the off-label status of the treatment. Documentation should note that the FDA has not reviewed Jatenzo for this age group, that no controlled trial data exist for children under 12, and that alternatives were considered and either tried or rejected with documented rationale.

Institutional review is advisable at academic medical centers. Some hospitals require that off-label use in children below a defined age be reviewed by a clinical ethics committee or pharmacy and therapeutics committee. Clinicians in private practice should document their decision-making process in detail.

The American Academy of Pediatrics policy on off-label drug use states: "When physicians use drugs in ways not approved by the FDA, they must be well informed about the drug, base its use on firm scientific rationale and sound medical evidence, and maintain records of the use of such therapy." [11] The absence of peer-reviewed controlled data on Jatenzo in children under 12 means "firm scientific rationale" must be constructed from indirect evidence, which places a higher documentation burden on the prescriber.

Summary of Evidence Quality

| Parameter | Evidence Level | Source | |---|---|---| | Jatenzo PK in children <12 | None (no published data) | N/A | | Epiphyseal closure risk with androgens | Established (observational data) | Multiple case series [7,8] | | BP elevation with Jatenzo | Established (adult RCT) | CLAR-15011 [1] | | Preferred alternatives in <12 | Guideline-supported | Endocrine Society 2010 [4] | | Benefit of testosterone <age 11 in Klinefelter | No demonstrated benefit | JCEM 2023 review [6] | | Topical T for micropenis | Small RCTs and case series | BJU International 2010 [5] |